Stoke Therapeutics Inc

NASDAQ:STOK  
50.60
+2.61 (+5.44%)
Other Pre-Announcement

Stoke Therapeutics Reports Q3 Loss Per Share $0.41

Published: 11/12/2020 12:51 GMT
Stoke Therapeutics, Inc. (STOK) - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates.
Q3 Loss per Share $0.41.
Q3 Earnings per Share Estimate $-0.41 -- Refinitiv Ibes Data (analyst estimates).
Stoke Therapeutics - As of Sept 30, 2020, Co Has $191.7 Million in Cash, Cash Equivalents and Restricted Cash, Anticipated to Fund Operations Into 2023.
Q3 Earnings per Share View $-0.41 -- Refinitiv Ibes Data (analyst estimates).
Expects to Complete Lead Optimization for Tango Asos Directed at Opa1 in 2021.
Preliminary Safety and Pharmacokinetic Data From Monarch Study Are Still Expected in 2021.